| Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ... The Lancet Oncology 21 (11), 1413-1422, 2020 | 752 | 2020 |
| Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition A Cruz-Bermúdez, R Laza-Briviesca, RJ Vicente-Blanco, ... Free Radical Biology and Medicine 135, 167-181, 2019 | 147 | 2019 |
| Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling A Cruz-Bermúdez, R Laza-Briviesca, RJ Vicente-Blanco, ... Free Radical Biology and Medicine 130, 163-173, 2019 | 122 | 2019 |
| Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial R Laza‐Briviesca, A Cruz‐Bermúdez, E Nadal, A Insa, ... Clinical and Translational Medicine 11 (7), e491, 2021 | 52 | 2021 |
| Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy M Casarrubios, A Cruz-Bermúdez, E Nadal, A Insa, MR García Campelo, ... Clinical Cancer Research 27 (21), 5878-5890, 2021 | 50 | 2021 |
| Umbilical cord blood plasma contains soluble NKG2D ligands that mediate loss of natural killer cell function and cytotoxicity ST Cox, R Laza‐Briviesca, H Pearson, B Soria, D Gibson, S Gomez, ... European Journal of Immunology 45 (8), 2324-2334, 2015 | 31 | 2015 |
| OA20. 02 pre-treatment levels of ctDNA for long-term survival prediction in stage IIIA NSCLC treated with neoadjuvant chemo-immunotherapy A Romero, E Nadal, R Serna, A Insa, MRG Campelo, C Benito, M Domine, ... Journal of Thoracic Oncology 16 (10), S883-S884, 2021 | 28 | 2021 |
| PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy A Cruz-Bermúdez, RJ Vicente-Blanco, R Laza-Briviesca, ... Scientific Reports 7 (1), 16661, 2017 | 26 | 2017 |
| Natural Killer Cells Improve Hematopoietic Stem Cell Engraftment by Increasing Stem Cell Clonogenicity In Vitro and in a Humanized Mouse Model M Escobedo-Cousin, N Jackson, R Laza-Briviesca, L Ariza-McNaughton, ... PLoS One 10 (10), e0138623, 2015 | 22 | 2015 |
| ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib A Romero, R Serna-Blasco, C Alfaro, E Sánchez-Herrero, M Barquín, ... Translational Lung Cancer Research 9 (3), 532, 2020 | 21 | 2020 |
| Elevation of IL‐17 cytokines distinguishes Kawasaki disease from other pediatric inflammatory disorders KE Brodeur, M Liu, D Ibanez, MJ de Groot, L Chen, Y Du, E Seyal, ... Arthritis & Rheumatology 76 (2), 285-292, 2024 | 20 | 2024 |
| The role of metabolism in tumor immune evasion: novel approaches to improve immunotherapy A Cruz-Bermúdez, R Laza-Briviesca, M Casarrubios, B Sierra-Rodero, ... Biomedicines 9 (4), 361, 2021 | 15 | 2021 |
| Functional characterisation and analysis of the soluble NKG2D ligand repertoire detected in umbilical cord blood plasma ST Cox, R Danby, D Hernandez, R Laza-Briviesca, H Pearson, ... Frontiers in immunology 9, 1282, 2018 | 15 | 2018 |
| OA20. 01 long term survival in operable stage Iiia Nsclc patients treated with neoadjuvant nivolumab plus chemotherapy-nadim study M Provencio, E Nadal, A Insa, MRG Campelo, D Pereiro, M Domine, ... Journal of Thoracic Oncology 16 (10), S883, 2021 | 14 | 2021 |
| Next-generation sequencing for tumor mutation quantification using liquid biopsies M Provencio, C Pérez-Barrios, M Barquin, V Calvo, F Franco, E Sánchez, ... Clinical Chemistry and Laboratory Medicine (CCLM) 58 (2), 306-313, 2020 | 14 | 2020 |
| Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy, and chemoimmunotherapy in resectable NSCLC P Rocha, J Zhang, R Laza-Briviesca, A Cruz-Bermúdez, ... Clinical Cancer Research 28 (11), 2461-2473, 2022 | 13 | 2022 |
| Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial B Sierra-Rodero, A Cruz-Bermúdez, E Nadal, Y Garitaonaindía, A Insa, ... Journal for immunotherapy of cancer 9 (8), e002804, 2021 | 9 | 2021 |
| P2. 04-10 biomarkers of pathological response on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients R Laza-Briviesca, A Cruz-Bermudez, M Casarrubios, E Nadal, A Insa, ... Journal of Thoracic Oncology 14 (10), S711, 2019 | 9 | 2019 |
| Characterization of 5′ promoter and exon 1–3 polymorphism of the RAET1E gene ST Cox, H Pearson, R Laza-Briviesca, S Pesoa, C Vullo, JA Madrigal, ... Human Immunology 77 (1), 96-103, 2016 | 9 | 2016 |
| KRAS p. G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor R Serna-Blasco, E Sánchez-Herrero, S Sanz-Moreno, A Rodriguez-Festa, ... ESMO open 6 (5), 100279, 2021 | 8 | 2021 |
